Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Neoplasms of the CNS

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    November 2024
  1. SINGER S, Schranz M, Hippler M, Kuchen R, et al
    Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
    Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653.
    PubMed     Abstract available


  2. CHAI TS, Rodgers-Fouche LH, Walls JO, Mattia AR, et al
    Real-world genetic testing outcomes of pan-cancer testing for mismatch repair deficiency.
    Cancer. 2024;130:3888-3893.
    PubMed     Abstract available


    October 2024
  3. AHMAD S, Muhlebner A, Snijders TJ, de Leng WW, et al
    Somatostatin receptor 2A expression in von Hippel-Lindau-related hemangioblastomas.
    Cancer. 2024;130:3473-3479.
    PubMed     Abstract available


    July 2024
  4. ASFAW ZK, Hernandez-Marquez GC, Germano IM
    Patients with glioblastoma: A tale of health care access and genetic ancestry.
    Cancer. 2024 Jul 8. doi: 10.1002/cncr.35470.
    PubMed    


    May 2024
  5. HSIEH AL, Bi WL, Ramesh V, Brastianos PK, et al
    Evolving concepts in meningioma management in the era of genomics.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35279.
    PubMed     Abstract available


    February 2024
  6. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    PubMed     Abstract available


    January 2024
  7. RANJAN S, Leung D, Ghiaseddin AP, Taylor JW, et al
    Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35220.
    PubMed     Abstract available


  8. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    PubMed     Abstract available


    October 2023
  9. LI Y, Cao J, Wang J, Wu W, et al
    Association of the m(6) A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer.
    Cancer. 2023 Oct 20. doi: 10.1002/cncr.35048.
    PubMed     Abstract available


  10. PAPINI C, Willard VW, Gajjar A, Merchant TE, et al
    Social cognition and adjustment in adult survivors of pediatric central nervous system tumors.
    Cancer. 2023;129:3064-3075.
    PubMed     Abstract available


    September 2023
  11. RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al
    Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030.
    PubMed     Abstract available


  12. LU S, Guo X, Li Y, Liu H, et al
    Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
    PubMed     Abstract available


    August 2023
  13. HEFFERNAN AE, Wu Y, Benz LS, Verhaak RGW, et al
    Quality of life after surgery for lower grade gliomas.
    Cancer. 2023 Aug 20. doi: 10.1002/cncr.34980.
    PubMed     Abstract available


  14. MAAS A, Maurice-Stam H, Kremer LCM, van der Aa-van Delden A, et al
    Psychosocial outcomes in long-term Dutch adult survivors of childhood cancer: The DCCSS-LATER 2 psycho-oncology study.
    Cancer. 2023;129:2553-2567.
    PubMed     Abstract available


  15. BAIREY O, Taliansky A, Glik A, Amiel A, et al
    A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
    Cancer. 2023 Aug 12. doi: 10.1002/cncr.34985.
    PubMed     Abstract available


    June 2023
  16. BALIGA S, Palmer JD, Yock TI
    Reply to "Is the hippocampus-sparing attempt really reasonable within the current technological possibilities?".
    Cancer. 2023;129:1779-1780.
    PubMed    


  17. ELMALI A, Mohammadipour S, Yazici G
    Is the hippocampus-sparing attempt really reasonable within the current technological possibilities?
    Cancer. 2023;129:1777-1778.
    PubMed    


    May 2023
  18. MULLER BARK J, Trevisan Franca de Lima L, Zhang X, Broszczak D, et al
    Proteome profiling of salivary small extracellular vesicles in glioblastoma patients.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34888.
    PubMed     Abstract available


  19. ESTEVEZ-ORDONEZ D, Abdelrashid M, Coffee E, Laskay NMB, et al
    Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort study.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34881.
    PubMed     Abstract available


  20. NEFF C, Price M, Cioffi G, Kruchko C, et al
    Complete prevalence of primary malignant and non-malignant brain tumors in comparison to other cancers in the United States.
    Cancer. 2023 May 18. doi: 10.1002/cncr.34837.
    PubMed     Abstract available


  21. BARDEN MM, Omuro AM
    Top advances of the year: Neuro-oncology.
    Cancer. 2023;129:1467-1472.
    PubMed     Abstract available


    April 2023
  22. COLE KA, Ijaz H, Surrey LF, Santi M, et al
    Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
    Cancer. 2023 Apr 20. doi: 10.1002/cncr.34786.
    PubMed     Abstract available


    December 2022

  23. Some patients with glioblastoma may benefit from epidermal growth factor receptor inhibition.
    Cancer. 2022;128:4175.
    PubMed    


  24. BALIGA S, Adams JA, Bajaj BVM, Van Benthuysen L, et al
    Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing.
    Cancer. 2022 Dec 11. doi: 10.1002/cncr.34574.
    PubMed     Abstract available


    October 2022
  25. WARREN LEG, Niman SM, Remolano MC, Landry JM, et al
    Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
    Cancer. 2022 Oct 10. doi: 10.1002/cncr.34441.
    PubMed     Abstract available


  26. PAPPO AS, Karol SE, Bertrand KC
    Top advances of the year: Pediatric oncology.
    Cancer. 2022;128:3593-3596.
    PubMed     Abstract available


    August 2022
  27. JOHANNET P, Simons M, Qian Y, Azmy N, et al
    Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma.
    Cancer. 2022 Aug 25. doi: 10.1002/cncr.34435.
    PubMed     Abstract available


    July 2022
  28. DEVINE KA, Christen S, Mulder RL, Brown MC, et al
    Recommendations for the surveillance of education and employment outcomes in survivors of childhood, adolescent, and young adult cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
    Cancer. 2022;128:2405-2419.
    PubMed     Abstract available


    April 2022
  29. MOORE KJ, Moertel CL, Williams LA
    Young adult males have worse survival than females that is largely independent of treatment received for many types of central nervous system tumors: A National Cancer Database analysis.
    Cancer. 2022;128:1616-1625.
    PubMed     Abstract available


  30. MOORE KJ, Moertel CL, Williams LA
    Minority children experience a higher risk of death from many central nervous system tumor types even after accounting for treatment received: A National Cancer Database analysis.
    Cancer. 2022;128:1605-1615.
    PubMed     Abstract available


  31. ROSSIDES M, Kampitsi CE, Talback M, Wiebert P, et al
    Childhood cancer risk in offspring of parents occupationally exposed to dusts: A register-based nested case-control study from Sweden of 5 decades.
    Cancer. 2022;128:1637-1648.
    PubMed     Abstract available


    March 2022
  32. PERLOW HK, Prasad RN, Yang M, Klamer B, et al
    Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.
    Cancer. 2022 Mar 22. doi: 10.1002/cncr.34192.
    PubMed     Abstract available


  33. CHEN X, Huang J, Xu N, Fan Z, et al
    A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
    Cancer. 2022 Mar 22. doi: 10.1002/cncr.34182.
    PubMed     Abstract available


    February 2022
  34. VUONG HG, Le HT, Dunn IF
    The prognostic significance of further genotyping H3G34 diffuse hemispheric gliomas.
    Cancer. 2022 Feb 23. doi: 10.1002/cncr.34156.
    PubMed     Abstract available


  35. DIAZ CORONADO RY, Mynarek M, Koelsche C, Mora Alferez P, et al
    Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients.
    Cancer. 2022;128:697-707.
    PubMed     Abstract available


    January 2022
  36. LEHRER EJ, Gurewitz J, Bernstein K, Patel D, et al
    Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study.
    Cancer. 2022 Jan 25. doi: 10.1002/cncr.34087.
    PubMed     Abstract available


  37. GRITSCH S, Batchelor TT, Gonzalez Castro LN
    Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system.
    Cancer. 2022;128:47-58.
    PubMed     Abstract available


  38. PHILLIPS NS, Khan RB, Li C, Mirzaei Salehabadi S, et al
    Seizures' impact on cognition and quality of life in childhood cancer survivors.
    Cancer. 2022;128:180-191.
    PubMed     Abstract available


    November 2021
  39. EMAMEKHOO H, Olsen MR, Carthon BC, Drakaki A, et al
    Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
    Cancer. 2021 Nov 16. doi: 10.1002/cncr.34016.
    PubMed     Abstract available


  40. LIU Y, Liu S, Li G, Li Y, et al
    Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas.
    Cancer. 2021 Nov 15. doi: 10.1002/cncr.34028.
    PubMed     Abstract available


    July 2021
  41. EATON BR, Fong GW, Ingerski LM, Pulsifer MB, et al
    Intellectual functioning among case-matched cohorts of children treated with proton or photon radiation for standard-risk medulloblastoma.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33774.
    PubMed     Abstract available


  42. PAULINO AC, Ludmir EB, Grosshans DR, Su JM, et al
    Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33783.
    PubMed     Abstract available


    June 2021
  43. WITHROW DR, Devesa SS, Deapen D, Petkov V, et al
    Nonmalignant meningioma and vestibular schwannoma incidence trends in the United States, 2004-2017.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33553.
    PubMed     Abstract available


    April 2021
  44. MOREIRA DC, Gajjar A, Patay Z, Boop FA, et al
    Creation of a successful multidisciplinary course in pediatric neuro-oncology with a systematic approach to curriculum development.
    Cancer. 2021;127:1126-1133.
    PubMed     Abstract available


    March 2021
  45. HANANIA AN, Paulino AC, Ludmir EB, Shah VS, et al
    Early radiotherapy preserves vision in sporadic optic pathway glioma.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33497.
    PubMed     Abstract available


  46. NANTAVITHYA C, Paulino AC, Liao K, Woodhouse KD, et al
    Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A surveillance, epidemiology, and end results analysis.
    Cancer. 2021 Mar 15. doi: 10.1002/cncr.33507.
    PubMed     Abstract available


  47. BANDER ED, Yuan M, Carnevale JA, Reiner AS, et al
    Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Cancer. 2021 Mar 2. doi: 10.1002/cncr.33459.
    PubMed     Abstract available


    January 2021
  48. REARDON DA, Kim TM, Frenel JS, Simonelli M, et al
    Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
    Cancer. 2021 Jan 26. doi: 10.1002/cncr.33378.
    PubMed     Abstract available


  49. PARK K, Jnne PA, Kim DW, Han JY, et al
    Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
    Cancer. 2021 Jan 12. doi: 10.1002/cncr.33385.
    PubMed     Abstract available


    June 2020
  50. HAJDU SI
    Pathfinders in oncology from the beginning of modern surgery of intracranial tumors to the introduction of the Pap smear.
    Cancer. 2020;126:2734-2749.
    PubMed     Abstract available


  51. KARSCHNIA P, Batchelor TT, Jordan JT, Shaw B, et al
    Primary dural lymphomas: Clinical presentation, management, and outcome.
    Cancer. 2020;126:2811-2820.
    PubMed     Abstract available


    May 2020
  52. CACHO-DIAZ B, Salmeron-Moreno K, Alvarez-Alvarez A, Mendoza-Olivas LG, et al
    Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms.
    Cancer. 2020 May 26. doi: 10.1002/cncr.32928.
    PubMed     Abstract available


    April 2020
  53. DALL'ERA MA, McPherson JD, Gao AC, DeVere White RW, et al
    Germline and somatic DNA repair gene alterations in prostate cancer.
    Cancer. 2020 Apr 21. doi: 10.1002/cncr.32908.
    PubMed     Abstract available


    March 2020
  54. RAUSCH CR, Jabbour EJ, Kantarjian HM, Kadia TM, et al
    Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Cancer. 2020;126:1152-1160.
    PubMed    


    November 2019
  55. ZHANG H, Zhu H, Deng G, Zito CR, et al
    PLEKHA5 regulates tumor growth in metastatic melanoma.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32611.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.